Novel PD-1 inhibitor shows activity against PD-L1 positive recurrent or metastatic cervical cancer
Enlonstobart, a fully humanized and high-affinity anti-PD-1 immunoglobulin G4 monoclonal antibody, shows therapeutic potential in patients with PD-L1 positive recurrent or metastatic cervical cancer (r/mCC), while having an acceptable safety profile, according to an open-label phase II study.
